Acerus Announces Resignation of Director

TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board of directors of the Company, effective immediately.

About Acerus

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Company ContactNaveed ManzoorChief Financial Officer[email protected]

Source: Acerus Pharmaceuticals Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission
• Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
• Aecon Announces Renewal of Normal Course Issuer Bid